The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelDrug costsCancer CenterLung cancerEpisode costsMean MedicareYale Cancer CenterClinical trial participationSystemic cancer therapyPart D drug costsCancer therapyLower drug costsCommon cancer typesChi-square testPayment modelsClinical factorsNovel cancer therapiesTrial participationOvarian cancerPatient episodesNovel therapiesCare modelCTR groupPharmaceutical costsAlternative payment modelsAdoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patternsThe impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodesThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapy